ProCE Banner Activity

DeLLphi-300: Long-term Follow-up From Phase I Study of Tarlatamab, a DLL3-Targeted Bispecific T-Cell Engager, in Previously Treated SCLC

Conference Coverage

In this long-term analysis, tarlatamab was associated with prolonged overall survival and intracranial activity in patients with previously treated SCLC.

Released: May 13, 2024

Expiration: May 12, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc